von Willebrand Factor Antigen Predicts Outcomes in Patients after Liver Resection of Hepatocellular Carcinoma

Schwarz, Christoph; Fitschek, Fabian; Mittlböck, Martina; Saukel, Veronika; Bota, Simona; Ferlitsch, Monika; Ferlitsch, Arnulf; Bodingbauer, Martin; Kaczirek, Klaus

doi:10.5009/gnl17115

Cited by 11 publications

(5 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…95 In addition, it may also predict liver failure following hepatectomy. 96 In summary, there is a plethora of simple blood-based biomarkers of portal hypertension; however, except for PLT (if combined with other parameters), none of the indirect markers of liver fibrosis markers is suitable for diagnosing CSPH in clinical practice. VWF (and possibly, VITRO score) showed a robust performance for diagnosing CSPH in patients with cACLD, while ELF/sCD163 has yet to be evaluated in this specific patient population.…”

Section: Blood-based Biomarkersmentioning

confidence: 99%

Noninvasive Diagnostics for Portal Hypertension: A Comprehensive Review

et al. 2020

View full text Add to dashboard Cite

Noninvasive diagnostics for portal hypertension include imaging and functional tests, as well as blood-based biomarkers, and capture different features of the portal hypertensive syndrome. Definitive conclusions regarding their clinical utility require assessment of their diagnostic value in specific clinical settings (i.e., diagnosing a particular hemodynamic condition within a well-defined target population). Several noninvasive methods are predictive of clinically significant portal hypertension (CSPH; hepatic venous pressure gradient [HVPG] ≥ 10 mm Hg; the threshold for complications of portal hypertension); however, only a minority of them have been evaluated in compensated advanced chronic liver disease (i.e., the target population). Importantly, most methods correlate only weakly with HVPG at high values (i.e., in patients with CSPH). Nevertheless, selected methods show promise for diagnosing HVPG ≥ 16 mm Hg (the cut-off for increased risks of hepatic decompensation and mortality) and monitoring HVPG changes in response to nonselective beta-blockers or etiological treatments. Finally, we review established and potential future clinical applications of noninvasive methods.

show abstract

Section: Blood-based Biomarkersmentioning

confidence: 99%

Noninvasive Diagnostics for Portal Hypertension: A Comprehensive Review

et al. 2020

View full text Add to dashboard Cite

show abstract

“…VWF, a complex plasma glycoprotein that facilitates platelet attachment to the endothelium [ 65 ], plays a pivotal role in hemostasis, tumor progression, and metastasis. Multiple studies have demonstrated that elevated plasma levels of VWF are linked to a poorer prognosis in patients with liver cancer, breast cancer, and NSCLC [ 66 , 67 ]. Additionally, the level of VWF can serve as a biomarker for the early diagnosis of liver cancer and lung adenocarcinoma [ 68 , 69 ].…”

Section: Discussionmentioning

confidence: 99%

Identification of exosome protein panels as predictive biomarkers for non-small cell lung cancer

Luo,

Que,

et al. 2023

Biol Proced Online

View full text Add to dashboard Cite

Background Non-small cell lung cancer (NSCLC) remains a leading cause of cancer-related deaths worldwide, primarily due to its propensity for metastasis. Patients diagnosed with localized primary cancer have higher survival rates than those with metastasis. Thus, it is imperative to discover biomarkers for the early detection of NSCLC and the timely prediction of tumor metastasis to improve patient outcomes. Methods Here, we utilized an integrated approach to isolate and characterize plasma exosomes from NSCLC patients as well as healthy individuals. We then conducted proteomics analysis and parallel reaction monitoring to identify and validate the top-ranked proteins of plasma exosomes. Results Our study revealed that the proteome in exosomes from NSCLC patients with metastasis was distinctly different from that from healthy individuals. The former had larger diameters and lower concentrations of exosomes than the latter. Furthermore, among the 1220 identified exosomal proteins, we identified two distinct panels of biomarkers. The first panel of biomarkers (FGB, FGG, and VWF) showed potential for early NSCLC diagnosis and demonstrated a direct correlation with the survival duration of NSCLC patients. The second panel of biomarkers (CFHR5, C9, and MBL2) emerged as potential biomarkers for assessing NSCLC metastasis, of which CFHR5 alone was significantly associated with the overall survival of NSCLC patients. Conclusions These findings underscore the potential of plasma exosomal biomarkers for early NSCLC diagnosis and metastasis prediction. Notably, CFHR5 stands out as a promising prognostic indicator for NSCLC patients. The clinical utility of exosomal biomarkers offers the potential to enhance the management of NSCLC.

show abstract

“…High expression of PDGFRB and MMP14 is associated with poor prognosis of HCC [ 36 – 38 ]. VWF has also been mentioned several times as a biomarker to predict the prognosis of liver cancer [ 33 , 39 , 40 ]. VWF is involved in the formation of microvascular thrombi during COVID19 pathogenesis [ 41 ].…”

Section: Discussionmentioning

confidence: 99%

Target and drug predictions for SARS-CoV-2 infection in hepatocellular carcinoma patients

et al. 2022

View full text Add to dashboard Cite

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the cause of the coronavirus disease (COVID-19), which poses a major threat to humans worldwide. With the continuous progress of the pandemic, a growing number of people are infected with SARS-CoV-2, including hepatocellular carcinoma (HCC) patients. However, the relationship between COVID-19 and HCC has not been fully elucidated. In order to provide better treatment for HCC patients infected with SARS-CoV-2, it’s urgently needed to identify common targets and find effective drugs for both. In our study, transcriptomic analysis was performed on both selected lung epithelial cell datasets of COVID-19 patients and the datasets of HCC patients to identify the synergistic effect of COVID-19 in HCC patients. What’s more, common differentially expressed genes were identified, and a protein-protein interactions network was designed. Then, hub genes and basic modules were detected based on the protein-protein interactions network. Next, functional analysis was performed using gene ontology terminology and the Kyoto Encyclopedia of Genes and Genomes pathway. Finally, protein-protein interactions revealed COVID-19 interaction with key proteins associated with HCC and further identified transcription factor (TF) genes and microRNAs (miRNA) with differentially expressed gene interactions and transcription factor activity. This study reveals that COVID-19 and HCC are closely linked at the molecular level and proposes drugs that may play an important role in HCC patients with COVID-19. More importantly, according to the results of our research, two critical drugs, Ilomastat and Palmatine, may be effective for HCC patients with COVID-19, which provides clinicians with a novel therapeutic idea when facing possible complications in HCC patients with COVID-19.

show abstract

von Willebrand Factor Antigen Predicts Outcomes in Patients after Liver Resection of Hepatocellular Carcinoma

Cited by 11 publications

References 37 publications

Noninvasive Diagnostics for Portal Hypertension: A Comprehensive Review

Noninvasive Diagnostics for Portal Hypertension: A Comprehensive Review

Identification of exosome protein panels as predictive biomarkers for non-small cell lung cancer

Target and drug predictions for SARS-CoV-2 infection in hepatocellular carcinoma patients

Contact Info

Product

Resources

About